Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Grant revenue	$ 1,526,482	$ 0	$ 4,654,294	$ 0
Operating expenses:
Research and development	1,791,487	330,543	5,583,149	955,784
General and administrative	2,410,124	573,511	4,403,590	1,580,927
Total operating expenses	4,201,611	904,054	9,986,739	2,536,711
Loss from operations	(2,675,129)	(904,054)	(5,332,445)	(2,536,711)
Other income (expense):
Other income (expense)	4,777,824	(88)	5,422,192	(1,769,093)
Interest income	47,667	21,519	100,778	30,157
Total other income (expense)	4,825,491	21,431	5,522,970	(1,738,936)
Net income (loss)	$ 2,150,362	$ (882,623)	$ 190,525	$ (4,275,647)
Earnings Per Share [Abstract]
Net income (loss) per share of common stock - basic (in dollars per share)	$ 0.65	$ (1.70)	$ 0.13	$ (8.25)
Weighted average shares outstanding - basic (in shares)	3,308,302	518,140	1,458,415	518,140
Net income (loss) per share of common stock - diluted (in dollars per share)	$ (0.70)	$ (1.70)	$ (2.37)	$ (8.25)
Weighted average shares outstanding - diluted (in shares)	3,766,700	518,140	2,209,407	518,140